Perforin (PRF1) as An Emerging Target for Type 1 Diabetes

Diabetes is a complex metabolic disorder which disrupts the balance of blood sugar in the body, affecting over 400 million people worldwide.¹ According to the World Health Organization (WHO), around 1.5 million deaths each year are directly attributable to diabetes, highlighting the critical need for research into this disease.¹

There are two main types of diabetes: Type 1 and Type 2. Type 1 diabetes arises when the body’s immune system mistakenly destroys insulin-producing cells in the pancreas.² Patients with Type 1 diabetes therefore rely on insulin administration for survival. In contrast, Type 2 diabetes is characterized by insulin resistance, where cells become unresponsive to insulin.³

While both types result in elevated blood sugar levels, they differ in terms of causes, onset, and treatment approaches. Type 1 diabetes is an autoimmune disease with no cure, whereas Type 2 is largely considered to be a preventative metabolic condition. As such, the development of more effective treatment options for Type 1 diabetes is critical. Therefore, in this target identification case study, we have chosen to focus specifically on Type 1 diabetes.

Rapid target identification accelerates the journey from research to clinical applications. Causaly allows the prioritization of potential drug targets based on causal relationships within diseases. Almost 2000 targets for Type 1 diabetes have been reported, according to Causaly, indicating significant research within this field. The evidence for these targets can be refined by linguistic strength, revealing ENY2 (a gene involved in transcription) as a potential target for Type 1 diabetes.

Using Causaly, targets can be refined by in vitro, preclinical, or clinical data, in addition to primary data coming from specific article sections. As an example, there are 421 specific targets for Type 1 diabetes identified in preclinical studies and reported in the results section. Two of the most recently reported targets for Type 1 diabetes are interleukins IL10 and IL4, cytokines which play key roles in immune response and inflammation. The anti-inflammatory effects of IL10 and IL4 were reported to be suppressed in mice with this disease.⁴ Another emerging target for Type 1 diabetes studied in mouse models was PRF1, published in February 2023.

PRF1, also known as perforin 1, is a protein encoded by the perforin gene, PRF1, which is instrumental in facilitating the destruction of cells in the immune system. Mutations in PRF1 can affect perforin function, which can impact immunological activity and increase the risk of autoimmunity.⁵ A study in 2023 implicated a possible link between PRF1 dysregulation and disease progression in mice with Type 1 diabetes.⁶ These findings indicate that PRF1 could serve as a promising therapeutic target to control immune responses, which could help minimize damage to insulin-producing cells in patients battling this disease.

The discovery of new targets for Type 1 diabetes research is vital in advancing our understanding of the disease and developing more effective treatment strategies. Continued exploration into the role of PRF1 in Type 1 diabetes could lead to innovative therapeutic approaches which may improve the quality of life for those affected by this condition.

For more articles on Target Discovery, download our latest Article Pack below: